Navigation Links
Sangamo BioSciences Reports 2007 Fourth Quarter and Year-End Financial Results
Date:2/5/2008

TF(TM)), designed to upregulate the vascular

endothelial growth factor-A (VEGF-A) gene.

-- Initiation of additional Phase 2 clinical trials of SB-509 in moderate

to severe DN (SB-509-701) and stem cell mobilization (SB-509-703). In

April, Sangamo announced the initiation of a randomized, single-blind,

placebo-controlled, repeat-dosing Phase 2 study designed to evaluate

the clinical safety and effects of repeat administration of SB-509 in

subjects that have moderate to severe DN (SB-509-701). In January

2008, Sangamo announced that it had initiated a randomized,

single-blind, placebo-controlled, multi-center Phase 2 clinical trial

(SB-509-703) in subjects with mild to moderate DN designed to evaluate

the pharmacokinetics of stem cell mobilization into the bloodstream

after treatment with varying doses of SB-509 as well as the clinical

safety and clinical effects of SB-509 administration.

-- Completion of enrollment of Phase 2 clinical trial of SB-509 for mild

to moderate DN (SB-509-601). In December, Sangamo announced that

enrollment was complete in a randomized, double-blind, repeat-dosing,

placebo-controlled, multi-center trial to evaluate SB-509 for the

treatment of mild to moderate DN. The company expects to have data

from this trial in the second half of 2008.

-- Establishment of major alliance with Sigma-Aldrich Corporation. In

July, as part of an agreement to develop and commercialize high value

laboratory research reagents based upon Sangamo's ZFP technology,

Sangamo received an upfront payment of $13.5 million which included

license fees and the purchase of one million shares of Sangamo stock.

Sangamo is also eligible to receive research funding, development and

commercial milestone payments of up to $24 m
'/>"/>

SOURCE Sangamo BioSciences, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related medicine technology :

1. Sangamo BioSciences Announces Completion of Enrollment of Phase 2 Clinical Trial of ZFP Therapeutic for Diabetic Neuropathy
2. Sangamo BioSciences and Sigma-Aldrich Announce Nature Biotechnology Study Demonstrating Zinc Finger Technology for Modification of Human Stem Cells
3. Neurocrine Biosciences Reports Fourth Quarter and Year-End 2007 Results
4. CeloNova BioSciences Introduces a New Class of Coronary Stent: The CATANIA(TM) Coronary Stent System with NanoThin Polyzene(R)-F
5. CeloNova BioSciences Announces Positive Results from European Study of Embozene(TM) Microspheres for Treatment of Uterine Fibroids
6. Epiphany Biosciences Reports Initiation of Phase 2 Study of Valomaciclovir for the Treatment of Acute Infectious Mononucleosis
7. Ardea Biosciences, Inc. Announces New Clinical Development Program Directed Toward the Treatment of Gout
8. Epiphany Biosciences Reports Initiation and Enrollment in Valomaciclovir Study for Shingles
9. Regado Biosciences Presents Early Stage Clinical Data for REG1 Anticoagulation System at American Heart Association 2007 Scientific Sessions
10. Regado Biosciences Presents Positive Data From REG1 Anticoagulation System Phase Ic Study at American Heart Association 2007 Scientific Sessions
11. Regado Biosciences Initiates Phase IIa Clinical Study of REG1 Anticoagulation System
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/20/2014)... , Oct. 20, 2014 Lpath, Inc. ... in bioactive lipid-targeted therapeutics, received official notification from the ... granted another key patent supporting its iSONEP™ and ... patent, European patent No. 2087002, claims compositions of ... Lpath,s two lead compounds, iSONEP and ASONEP. Sonepcizumab ...
(Date:10/20/2014)... Norgine B.V. today announced that the Phase ... NER1006, presented at the 79 th Annual Scientific ... Philadelphia, PA , has met its primary ... of cleansing success. The study demonstrated high quality bowel ... screening colonoscopy patients. [1] (Logo: http://photos.prnewswire.com/prnh/20130829/633895-a) ...
(Date:10/19/2014)... CTI BioPharma Corp. (CTI) (NASDAQ and MTA: ... quarter 2014 financial results on Wednesday, October 29, 2014, ... the announcement, members of the management team will host ... provide a general corporate update at 4:30 p.m. EDT ... obtained as follows: Wednesday, October 29 ...
Breaking Medicine Technology:Lpath Granted Key European Patent Related to iSONEP and ASONEP Programs 2Lpath Granted Key European Patent Related to iSONEP and ASONEP Programs 3Lpath Granted Key European Patent Related to iSONEP and ASONEP Programs 4Positive Results from Phase II Data Show NER1006 Achieves High Quality Bowel Cleansing Efficacy 2CTI BioPharma to Report Third Quarter 2014 Financial Results on October 29, 2014 2
... April 12, 2011 Visual Healthcare Corp. (the "Company") (NASDAQ ... Chinese based adaptation of the information technology grid that its ... This project has been launched in response to requests from ... experts responding to Chinese government resolve to create a major ...
... 2011 Southern Home Medical Equipment, Inc. (PINKSHEETS: ... professionals and equipment to medical institutions, announced today ... for fiscal year 2010 have been restated to ... Staffing. In a previous announcement dated ...
Cached Medicine Technology:Visual Healthcare to Support Chinese Clinical Trials 2Visual Healthcare to Support Chinese Clinical Trials 3Southern Home Medical Equipment Reports Additional Revenues and Profits for 2010 2
(Date:10/20/2014)... October 20, 2014 Houston plastic surgeon ... the key elements of his innovative True Form ... plastic surgery residents and faculty at The University ... he, too, was once a medical student. Patronella, who ... private cosmetic plastic surgery practices in Texas, The ...
(Date:10/19/2014)... Hastings and Hastings, a Phoenix personal injury law ... greater Phoenix area and across Arizona reports record demand ... automobile accidents. Statistics have indicated a steady increase in ... such, Hastings and Hastings has seen a steady increase ... have been injured through no fault of their own ...
(Date:10/19/2014)... 2014 Recently, BambooIndustry.com, one of the ... new range of bamboo deckings . Moreover, the ... items; they are now available at deeply discounted rates. ... is hard to overstate the significance of online business ... online services. The company’s workers are striving to deliver ...
(Date:10/19/2014)... Texas (PRWEB) October 20, 2014 ... development for Partial Seizure, complete with comparative analysis ... mechanism of action (MoA), route of administration (RoA) ... featured news and press releases. It also reviews ... Partial Seizure and special features on late-stage and ...
(Date:10/19/2014)... 20, 2014 Recently, Top10BestSEOHosting.com has ... that JustHost, GoDaddy and HostMonster are the best ... (Virtual Private Server) is the method of partitioning ... of which has the appearance and capabilities of ... why the site pays close attention to VPS ...
Breaking Medicine News(10 mins):Health News:Plastic Surgeon Patronella Presents Artistically-Inspired Tummy Tuck Method to Future Generation of Plastic Surgeons in Texas 2Health News:Hastings And Hastings Reports Record Demand In 2014 For Legal Representation With Regard To Catastrophic Automobile Accidents 2Health News:Hastings And Hastings Reports Record Demand In 2014 For Legal Representation With Regard To Catastrophic Automobile Accidents 3Health News:High Quality Bamboo Deckings, New Items Unveiled By BambooIndustry.com 2Health News:Partial Seizure Therapeutic Pipeline Market Review H2 2014 in a New Report Available at RnRMarketResearch.com 2Health News:Partial Seizure Therapeutic Pipeline Market Review H2 2014 in a New Report Available at RnRMarketResearch.com 3Health News:Partial Seizure Therapeutic Pipeline Market Review H2 2014 in a New Report Available at RnRMarketResearch.com 4Health News:The Best VPS Hosting Suppliers In The Market Unveiled By Top10BestSEOHosting.com 2
... 12 The Ensign Group, Inc. (Nasdaq: ... Ensign(TM) group of skilled nursing, rehabilitative care services ... of Suzanne D. Snapper to succeed soon-to-be-retiring CFO ... , Ms. Snapper has been serving as ...
... MedApps, Enabling Mobile Wireless Technology Links Patients, Care ... Retail Off-the-Shelf Medical DevicesSCOTTSDALE, Ariz., May 12 ... provide a new, convenient and cost effective solution ... health record. MedApps, HealthPAL is a unique solution ...
... Carbon Footprint at DaVita,s Six Corporate Business OfficesEL SEGUNDO, ... DVA ), a leading provider of kidney care services ... announced that the company is the first FORTUNE 500 ... (EPA) Green Power Partnership program. Joining this program is ...
... 12 Occlutech, the leading European,developer of septum occluders, today ... generation ASD and PFO occluders, the Figulla Flex. , ... encompass a new innovative,delivery system, making the use of a ... the ability of the delivery,system to allow a 45 degree ...
... will present technology and admissions educational sessions for ACHCA members ... ... 12, 2009 --Patient Placement Systems, the leading provider of automated ... will exhibit and present two sessions at the American College ...
... love its usability & CCHIT recognizes its functionality; CureMD EHR ... ... New York, NY (PRWEB) May 12, 2009 -- The Certification ... EHR v10 complies with updated interoperability requirements, is a conditionally ...
Cached Medicine News:Health News:The Ensign Group Announces the Retirement of CFO Alan J. Norman; Names Suzanne D. Snapper as New Chief Financial Officer 2Health News:MedApps HealthPAL Connects to Microsoft HealthVault to Improve Patient Compliance and Lower Healthcare Costs 2Health News:MedApps HealthPAL Connects to Microsoft HealthVault to Improve Patient Compliance and Lower Healthcare Costs 3Health News:DaVita Becomes the First FORTUNE 500 Healthcare Services Company to Join the EPA Green Power Partnership 2Health News:DaVita Becomes the First FORTUNE 500 Healthcare Services Company to Join the EPA Green Power Partnership 3Health News:Patient Placement Systems Presenting Two Sessions at ACHCA 2009 Convocation 2Health News:Patient Placement Systems Presenting Two Sessions at ACHCA 2009 Convocation 3Health News:Doctors Love its Usability & CCHIT Recognizes its Functionality; CureMD EHR v10 CCHIT 08 Certified 2Health News:Doctors Love its Usability & CCHIT Recognizes its Functionality; CureMD EHR v10 CCHIT 08 Certified 3
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
Medicine Products: